- JP-listed companies
- K Pharma,Inc.
- Cash flow
K Pharma,Inc. (4896) Cash flow
Market cap
¥7.6B
P/E ratio
-4.7x
K Pharma develops treatments for neurological diseases like ALS and Alzheimer's using iPS cell technology and regenerative medicine based on Keio University research.
| 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 7 | - | - | - | - |
| Cash from operations | -196 | -363 | 454 | -984 | -918 |
| Capital expenditures | - | -30 | -10 | -14 | -11 |
| Cash from investing | -0 | -33 | -11 | -14 | -55 |
| Cash from financing | 368 | 1,544 | 1,486 | - | 1,496 |